|Bid||2.1700 x 3000|
|Ask||2.9900 x 900|
|Day's Range||2.8140 - 2.9215|
|52 Week Range||2.4000 - 4.9800|
|Beta (3Y Monthly)||-0.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nanocap medical device company NanoVibronix (NASDAQ: NAOV ) announced it's developing cannabidiol patches and cream utilizing a proprietary and nanoparticle-based infusion process. CBD is one of the naturally ...
NanoVibronix (NAOV) filed their 10-Q for Q1 2019 ending March 31st and released a corresponding business update. OTC approval, if and when achieved, would be a major milestone as it would allow for purchase and use of PainShield without the need for a doctor’s prescription – which has been a major impediment to sales to-date.
Each day they completed a Visual Analog Scale (indicating pain severity) and medication logs (reporting how much pain medication they took). In addition, while control saw a 1.5% decrease in breakthrough pain medication use (including opioids), PainShield patients used 46.4% less. The improvements in VAS scores as well as in the amount of pain medications used (both favoring PainShield) were statistically significant (charts below).
Zacks SCR Senior Med-Tech analyst and Director of Research Brian Marckx, CFA has initiated coverage of NanoVibronix, Inc. with a $9.00/share price target. NanoVibronix, Inc. (NAOV), develops, manufactures and commercializes proprietary low intensity low frequency wearable ultrasound medical devices for the treatment of pain, reduction in bacterial colonization and biofilm disruption, and for wound healing. The relative safety of low intensity, low frequency ultrasound and compact size and simple operation of NAOV’s technology lend themselves to at-home use.